Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term efficacy of intravenous Bondronat 6 mg loading doses for metastatic bone pain in breast cancer
2006-002180-72Phase 2Completed
- Sponsor
- Roche
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibandronic acid in breast cancer, bone metastases and breast cancer bone metastases (BCBM), sponsored by Roche. Primary endpoint: Bone pain response within 7 days. Started May 2006; status: completed.
02
Drugs
ibandronic acid
03
Conditions
breast cancerbone metastasesbreast cancer bone metastases (BCBM)
Beyond the preview
Go deeper on 2006-002180-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002180-72.